Navigation Links
Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010
Date:9/8/2010

Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 -- SHENZHEN, China, Sept. 8 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, Personnel Announcements Click to view news release full screen  

Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010

 

SHENZHEN, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that on September 3, 2010, Mr. Charles Wang submitted his resignation as Chief Financial Officer for personal reasons and not as a result of any disagreement with the Company regarding financial or accounting practices. The resignation will be effective on December 2, 2010.

Mr. Charles Wang is expected to stay with the company until December. The Company has commenced an executive search in order to find a replacement.

Xiaochun Wang, Tongjitang's Chief Executive Officer and Chairman of the Board of Directors, stated, "On behalf of the Board, management, and employees of our company, I'd like to thank Mr. Charles Wang for his dedication and contribution to Tongjitang over the past two years and wish him all the best on his future endeavors."

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante, Anhui Jingfang and Gui Liqour Ltd., is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 35 other modernized traditional Chinese medicine products and 36 western medicines. Please visit http://www.tongjitang.com for more information.

For more information, please contact: ICR, Inc. Ashley M. Ammon or Christine Duan Phone: +1-203-682-8200 (Investor Relations)
'/>"/>

SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tongjitang Chinese Medicines Company Reports Second Quarter 2010 Financial Results
2. Tongjitang Files 2009 Annual Report on Form 20-F
3. Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
4. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
5. China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
6. China BCT Signs Exclusive Distribution Contract With Liujiang County Chinese Medicine Hospital
7. Biosites Triage Products Seized by Beijing Customs; Chinese Market Facing Shortage
8. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
9. Chinese Distribution Contract Extended for an Additional 4 Years
10. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Potrero Medical, Inc., the developer of the ... appointment of George M. Rapier, III , MD, to ... , WellMed is one of the nation,s largest physician ... members in Texas and ... his own internal medicine practice, he has been instrumental to ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... SEOUL, South Korea , Feb. 11, 2016 Wearable posture tracker, ALEX , has ... project fully funded and just seven days left to go, ALEX is said to be delivered to ... http://photos.prnewswire.com/prnh/20160211/332248 ... ... ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Image One USA veteran franchise owner Maria Bogacki is bringing ... Nashville that will benefit. , “I’ve enjoyed being a part of the Image One ... question that I would bring my business with me,” Bogacki said. “The entire Image ...
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine ... Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital area. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
Breaking Medicine News(10 mins):